Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

513
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
513
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

590
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
590
Dementia01:30

Dementia

131
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
131
Psychosis: Pathophysiology of Schizophrenia and Other Psychotic Disorders01:27

Psychosis: Pathophysiology of Schizophrenia and Other Psychotic Disorders

721
Schizophrenia is a neurodevelopmental disorder whose origins are rooted in complex genetic components. Despite our burgeoning understanding, the pathophysiology of this disorder remains incompletely deciphered.
Researchers have identified genetic factors that increase susceptibility to schizophrenia, underscoring the intricate interplay between genetics and environment in disease development. At the core of schizophrenia's pathophysiology is excessive dopaminergic neurotransmission within...
721
Disorders of the Nervous Tissue01:28

Disorders of the Nervous Tissue

1.4K
Nervous tissue is a vital component of the human body's communication system, enabling us to perceive and respond to stimuli. However, like all other tissues, it is vulnerable to disorders and diseases that can significantly impact our neurological functioning.
Homeostatic Imbalances:
Alzheimer's disease manifests as a gradual decline in memory and cognitive abilities, attributed to the buildup of amyloid plaques and neurofibrillary tangles in the brain.
Parkinson's disease arises from the...
1.4K
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

6.3K
Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
6.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

APOE4 Drives Uniquely Dysfunctional Human Microglial States in Alzheimer's Disease.

bioRxiv : the preprint server for biology·2026
Same author

Potential glutamatergic and GABAergic false neurotransmitters in models of excitation-inhibition imbalance.

Scientific reports·2026
Same author

Plant-Based Dietary Patterns and Risk of Alzheimer Disease and Related Dementias in the Multiethnic Cohort Study.

Neurology·2026
Same author

Comparative Analysis of T-Cell Signatures and Astroglial Reactivity in Parkinson's Pathology Across Animal Models with Distinct Regenerative Capacities.

International journal of molecular sciences·2026
Same author

Developing Topics.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2025
Same author

Epigenomic profile of GBA1 in Parkinson's disease.

Parkinsonism & related disorders·2025

Related Experiment Video

Updated: Jul 16, 2025

Symmetric Bihemispheric Postmortem Brain Cutting to Study Healthy and Pathological Brain Conditions in Humans
08:29

Symmetric Bihemispheric Postmortem Brain Cutting to Study Healthy and Pathological Brain Conditions in Humans

Published on: December 18, 2016

14.1K

Paradigm Shift: Multiple Potential Pathways to Neurodegenerative Dementia.

Amalia Perna1, Kathleen S Montine2, Lon R White3

  • 1Department of Pathology, Stanford University, 300 Pasteur Dr., Stanford, CA, 94305, USA. amaliap@stanford.edu.

Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics
|September 21, 2023
PubMed
Summary

Effective dementia treatment requires a shift towards personalized, multimodal therapies. Addressing complex comorbidities and neurodegenerative processes is crucial for advancing treatments beyond symptom management for conditions like Alzheimer's disease.

Keywords:
Alzheimer’s diseaseDementiaLewy body diseaseMicrogliaNeuropathologic comorbidity

More Related Videos

An Alternative Approach to Study Primary Events in Neurodegeneration Using Ex Vivo Rat Brain Slices
07:57

An Alternative Approach to Study Primary Events in Neurodegeneration Using Ex Vivo Rat Brain Slices

Published on: April 11, 2018

7.0K
Viability Assays for Cells in Culture
12:03

Viability Assays for Cells in Culture

Published on: January 20, 2014

46.3K

Related Experiment Videos

Last Updated: Jul 16, 2025

Symmetric Bihemispheric Postmortem Brain Cutting to Study Healthy and Pathological Brain Conditions in Humans
08:29

Symmetric Bihemispheric Postmortem Brain Cutting to Study Healthy and Pathological Brain Conditions in Humans

Published on: December 18, 2016

14.1K
An Alternative Approach to Study Primary Events in Neurodegeneration Using Ex Vivo Rat Brain Slices
07:57

An Alternative Approach to Study Primary Events in Neurodegeneration Using Ex Vivo Rat Brain Slices

Published on: April 11, 2018

7.0K
Viability Assays for Cells in Culture
12:03

Viability Assays for Cells in Culture

Published on: January 20, 2014

46.3K

Area of Science:

  • Neuroscience
  • Pharmacology
  • Geriatrics

Background:

  • Neurodegenerative dementias stem from complex abnormalities like neurotransmitter imbalances and protein aggregation.
  • Current Alzheimer's disease (AD) treatments offer modest benefits and focus on symptoms or disease structures.
  • Multiple neurodegenerative processes often co-occur, complicating treatment development.

Purpose of the Study:

  • To highlight the limitations of current dementia therapeutics.
  • To emphasize the need for a paradigm shift in dementia treatment strategies.
  • To discuss emerging therapeutic avenues and challenges in dementia research.

Main Methods:

  • Review of current understanding of neurodegenerative dementia.
  • Analysis of recent FDA-approved and investigational therapies for dementia.
  • Discussion of the impact of comorbidities on therapeutic effectiveness.

Main Results:

  • Existing dementia treatments, including aducanumab and lecanemab, show limited efficacy.
  • New therapeutic strategies are exploring cognition enhancement, drug combinations, and targeting neuroinflammation or the microbiome.
  • Underlying comorbidities significantly impact treatment response but are difficult to identify during life.

Conclusions:

  • A paradigm shift towards individualized and multimodal treatment approaches is necessary for effective dementia therapeutics.
  • Future therapies may involve modifying microglia or other novel biological targets.
  • Accurate identification of comorbidities is vital to improve clinical trial success and optimize patient care.